Pasireotide - RECORDATI
Alternative Names: Pashireochidopamo salt; pasireotide LAR; Pasireotide pamoate; SIGNIFOR; SIGNIFOR LAR; SOM 230; SOM 230 LAR; SOM230CLatest Information Update: 23 Jan 2024
At a glance
- Originator Novartis
- Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis; Recordati; UNC Lineberger Comprehensive Cancer Center; University of Arkansas for Medical Sciences; University of Miami
- Class Analgesics; Antineoplastics; Antisecretories; Cyclic peptides; Macrocyclic compounds; Oligopeptides; Peptidomimetics
- Mechanism of Action Corticotropin-releasing hormone inhibitors; Growth hormone-releasing hormone inhibitors; Insulin-like growth factor I inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acromegaly; Gigantism; Pituitary ACTH hypersecretion
- Phase II Cluster headache; Hypoglycaemia; Pituitary cancer
- Discontinued Carcinoid tumour; Gastrointestinal cancer; Gastrointestinal disorders; Liver cancer; Malignant melanoma; Meningioma; Merkel cell carcinoma; Neuroendocrine tumours; Pancreatic cancer; Pancreatic disorders; Prostate cancer; Radiation injuries; Uveal melanoma
Most Recent Events
- 04 Jan 2024 Phase-II clinical trials in Hypoglycaemia in Switzerland (SC) (NCT05928390)
- 03 Jul 2023 Recordati plans a phase II trial for Hypoglycaemia (IV) in October 2023 (NCT05928390)
- 02 Mar 2023 H. Lee Moffitt Cancer Center and Research Institute in collaboration with Novartis and Recordati complete a phase II trial for Neuroendocrine tumours (Metastatic disease; Inoperable/Unresectable) in the US (IM) (NCT01253161)